Clinical Trial Update: Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM) [Phase 1, Phase 2]

View source ↗

Summary

This is a Phase 1/2 clinical trial update evaluating first-line treatment of malignant pleural mesothelioma with a carboplatin, bevacizumab, and pemetrexed comb…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• Alimta (pemetrexed)
• Avastin (bevacizumab)
• CARBOPLATIN (Carboplatin)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Mesothelioma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2011-12-26